Fig. 2From: A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancerDuration on therapy. a Number of cycles of therapy for each patient. Cycles are 28 days. b Progression-free survival curveBack to article page